Texas Heart Institute Home
Continuing Medical Education
 
CME Home
 

To participate in this event:
1. Read CME information.
2. View course materials.
3. Complete assessment. 
4. Obtain CME credit.

 
 

PAR-1 and Next-generation Antiplatelet Therapy in Cardiovascular Medicine

Date of Online Release: June 2, 2009
Recent review: December 2013
Termination Date: December 9, 2014
Credits: .75 AMA PRA Category 1 Credit™
See link to Course Materials below.


CME Information - Overview

Thrombin receptor (PAR-1) antagonist represents a new arena of pharmacotherapy for acute coronary syndromes and percutaneous coronary revascularization. New-generation intravenous and reversible ADP receptor (P2Y12) antagonists are discussed. 

Educational Objectives
The intended result of this activity is increased knowledge. At the conclusion of this presentation, participants should be able to-

  • Describe the biologic importance of the platelet thrombin receptor.
  • Interpret available phase II data for PAR-1 antagonists.
  • Classify new-generation P2&12 receptor blockers. 

Target Audience
The intended audience for this continuing medical education activity includes cardiologists, internists, and research scientists.

Method of Instruction / Participation
This online enduring material comprises slide sets with text and audio derived from a live cardiology grand rounds presentation with post activity assessment and evaluation.

Evaluation / Feedback
We value your feedback; please send your suggestions and comments to the office of continuing medical education at Texas Heart Institute.

Speaker

   David J. Moliterno, MD 


David J. Moliterno
, MD
University of Kentucky
Lexington, Kentucky





Acknowledgement of Support
No grants were received for the production of this online enduring material.

Accreditation / Credit Designation 

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Texas Heart Institute designates this educational activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Estimated Study Time
The estimated time to complete this activity, including review of the materials and completion of the course assessment is 45 minutes.

Repurposing Statement
If you previously completed and received credit for the live CME-sponsored grand rounds entitled, PAR-1 and Next-generation Antiplatelet Agents in Cardiovascular Medicine, on April 24, 2009, please note that you will not receive credit for completing this activity. Participants who take part in an identical activity, even in order to validate learning or to clarify specific topics, cannot claim, nor will the Texas Heart Institute award, duplicate credit for the activity.

Disclosure of Relationships
It is the intent of the Texas Heart Institute to ensure that its educational mission and its continuing medical activities in particular, should not be influenced by the special interests of individuals associated with its program.

Faculty Disclosure
In accordance with the guidelines of the Accreditation Council for Continuing Medical Education, faculty members have disclosed their relationships, either with one or more of the manufacturers of commercial products discussed, or with one or more of the corporate organizations offering educational grants for the live continuing medical education activity.

David J. Moliterno, MD discloses the following, relevant to this program: Consultant: Schering Plough Corporation and Portola Pharmaceuticals, Inc. In addition, he discusses unlabeled or investigational uses of products.
Course Materials and CME Credit 

This online enduring material comprises one presentation. By clicking on the course materials link, you acknowledge that you have reviewed the CME information provided above. After viewing the presentation, you must complete an assessment and evaluation to obtain CME credit for this activity.

Course Materials

Return to Explore Online Courses.
 
Find Us on Facebook!

Please contact our Webmaster with questions or comments.
Terms of Use and Privacy Policy
© Copyright Texas Heart Institute. All rights reserved.
Texas Heart Institute, Texas Heart, Texas Heart Institute Journal, THI, Heart Owner's, Leading With the Heart and Heart of Discovery are members of the
family of trademarks of the Texas Heart Institute.


U.S. NEWS America's Best Hospitals 2012-13